BR112016018489A2 - Método de qualificação de células, população isolada de células-tronco mesenquimais, método de tratamento de uma doença imune ou inflamatória, e uso de células-tronco mesenquimais - Google Patents

Método de qualificação de células, população isolada de células-tronco mesenquimais, método de tratamento de uma doença imune ou inflamatória, e uso de células-tronco mesenquimais

Info

Publication number
BR112016018489A2
BR112016018489A2 BR112016018489A BR112016018489A BR112016018489A2 BR 112016018489 A2 BR112016018489 A2 BR 112016018489A2 BR 112016018489 A BR112016018489 A BR 112016018489A BR 112016018489 A BR112016018489 A BR 112016018489A BR 112016018489 A2 BR112016018489 A2 BR 112016018489A2
Authority
BR
Brazil
Prior art keywords
mesenchymal stem
stem cells
population
qualification
immune
Prior art date
Application number
BR112016018489A
Other languages
English (en)
Inventor
Gothelf Yael
Levy Yosef
Original Assignee
Brainstorm Cell Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brainstorm Cell Therapeutics Ltd filed Critical Brainstorm Cell Therapeutics Ltd
Publication of BR112016018489A2 publication Critical patent/BR112016018489A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5073—Stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/13—Nerve growth factor [NGF]; Brain-derived neurotrophic factor [BDNF]; Cilliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurotrophins [NT]; Neuregulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/135—Platelet-derived growth factor [PDGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/195—Heregulin, neu differentiation factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/58—Adhesion molecules, e.g. ICAM, VCAM, CD18 (ligand), CD11 (ligand), CD49 (ligand)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Analytical Chemistry (AREA)
  • Rheumatology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)

Abstract

MÉTODO DE QUALIFICAÇÃO DE CÉLULAS, POPULAÇÃO ISOLADA DE CÉLULAS-TRONCO MESENQUIMAIS, MÉTODO DE TRATAMENTO DE UMA DOENÇA IMUNE OU INFLAMATÓRIA, E USO DE CÉLULAS-TRONCO MESENQUIMAIS. Compreende um método para qualificação de se uma população de célula é um terapêutico adequado é revelado. O método compreende: (a) incubar uma população de células-tronco mesenquimais (MSCs) não diferenciadas em um meio de diferenciação, compreendendo fator de crescimento derivado de fibroblasto básico (bFGF), fator de crescimento derivado de plaqueta (PDGF), heregulina e cAMP por, pelo menos, dois dias para obter uma população de MSCs diferenciadas; e (b) analisar a expressão de CD49a na população de MSC diferenciada em que uma quantidade de CD49a acima de um nível predeterminado é indicativo da população de célula que é adequada como um terapêutico.
BR112016018489A 2014-02-11 2015-02-11 Método de qualificação de células, população isolada de células-tronco mesenquimais, método de tratamento de uma doença imune ou inflamatória, e uso de células-tronco mesenquimais BR112016018489A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461938172P 2014-02-11 2014-02-11
PCT/IL2015/050159 WO2015121859A1 (en) 2014-02-11 2015-02-11 Method of qualifying cells

Publications (1)

Publication Number Publication Date
BR112016018489A2 true BR112016018489A2 (pt) 2017-08-08

Family

ID=52682791

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016018489A BR112016018489A2 (pt) 2014-02-11 2015-02-11 Método de qualificação de células, população isolada de células-tronco mesenquimais, método de tratamento de uma doença imune ou inflamatória, e uso de células-tronco mesenquimais

Country Status (8)

Country Link
US (1) US10564149B2 (pt)
EP (1) EP3105587B1 (pt)
JP (1) JP6628253B2 (pt)
BR (1) BR112016018489A2 (pt)
CA (1) CA2937305C (pt)
HK (1) HK1232296A1 (pt)
IL (1) IL246943B (pt)
WO (1) WO2015121859A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2880151B1 (en) 2012-08-06 2020-06-03 Brainstorm Cell Therapeutics Ltd. Methods of generating mesenchymal stem cells which secrete neurotrophic factors
CA2937305C (en) 2014-02-11 2020-12-15 Brainstorm Cell Therapeutics Ltd. Pharmaceutical composition comprising bone-marrow derived mesenchymal stem cells
JP6998768B2 (ja) 2015-08-28 2022-02-10 ロート製薬株式会社 Ｒｏｒ１陽性の間葉系幹細胞及びその調製方法、ｒｏｒ１陽性の間葉系幹細胞を含む医薬組成物及びその調製方法、並びにｒｏｒ１陽性の間葉系幹細胞を用いる疾患の予防又は治療方法
JP6153653B2 (ja) * 2015-12-07 2017-06-28 株式会社Ｃｅｌｌｓ Ｐｏｗｅｒ 幹細胞培養方法
AU2017235446A1 (en) * 2016-03-16 2018-11-08 Cell Medicine, Inc. Mesenchymal stem cells with enhanced efficacy
KR20220126789A (ko) 2016-07-18 2022-09-16 브레인스톰 셀 세라퓨틱스 리미티드 근위축성 측색 경화증 (als)의 치료 방법
CN108559729B (zh) * 2018-02-05 2022-01-14 上海科技大学 Fam49基因及其编码蛋白的应用
EP3773620A1 (en) * 2018-04-10 2021-02-17 Brainstorm Cell Therapeutics Ltd. Cell-type specific exosomes and use thereof
WO2020081903A1 (en) * 2018-10-18 2020-04-23 Quadrant Biosciences Inc. Molecular and functional characterization of early-stage parkinson's disease and treatments therein
WO2020086667A1 (en) 2018-10-25 2020-04-30 American University Method for promoting adipocyte differentiation and obesity-related disease treatment
CN111979186B (zh) * 2020-08-21 2022-04-08 遵义医科大学附属医院 一种快速高效体外扩增人间充质干细胞的方法及应用

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
JP3948971B2 (ja) 2001-08-30 2007-07-25 サンバイオ，インコーポレイティド Ｎｏｔｃｈ遺伝子の導入を用いて骨髄間質細胞を神経細胞及び骨格筋細胞に分化・誘導する方法
CA2475288C (en) 2002-02-06 2014-09-02 Sanbio, Inc. Method of inducing differentiation of bone marrow stromal cells to neural cells or skeletal muscle cells by introduction of notch gene
IL152905A0 (en) 2002-11-17 2003-06-24 Univ Ramot Dopaminergic markers induction in neuronal-like cells isolated from adult human bone marrow stromal cells: implications for novel gene therapy strategy for parkinsons disease
CN101243178A (zh) * 2005-06-16 2008-08-13 特拉维夫大学拉莫特有限公司 用于治疗cns疾病的分离细胞和包含这种细胞的细胞群
US20100021434A1 (en) 2005-12-08 2010-01-28 Ramot At Tel Aviv University Ltd. Isolated Oligodendrocyte-Like Cells and Populations Comprising Same for the Treatment of CNS Diseases
EP3514229A1 (en) * 2008-05-28 2019-07-24 Ramot at Tel-Aviv University Ltd. Mesenchymal stem cells for the treatment of cns diseases
US20100184033A1 (en) * 2008-07-16 2010-07-22 West Michael D Methods to accelerate the isolation of novel cell strains from pluripotent stem cells and cells obtained thereby
GB0814249D0 (en) * 2008-08-04 2008-09-10 Cellerix Sa Uses of mesenchymal stem cells
EP2501802A4 (en) * 2009-11-17 2013-08-21 Advanced Cell Tech Inc METHOD FOR PRODUCING HUMAN RPE CELLS AND PHARMACEUTICAL PREPARATIONS FROM HUMAN RPE CELLS
ES2600321T3 (es) * 2011-08-04 2017-02-08 Ethianum Betriebsgesellschaft Mbh & Co. Kg Medios para la regeneración del hígado
DE102011121982B3 (de) * 2011-12-22 2013-04-18 Dietmar Hopp Stiftung GmbH Mesenchymale Stammzellen aus Fettgewebe (ADSC) zur Rekonstruktion von Haut und Weichteilgewebe
CA2876499C (en) * 2012-07-12 2021-10-26 Imstem Biotechnology, Inc. Mesenchymal-like stem cells derived from human embryonic stem cells, methods and uses thereof
EP2880151B1 (en) 2012-08-06 2020-06-03 Brainstorm Cell Therapeutics Ltd. Methods of generating mesenchymal stem cells which secrete neurotrophic factors
CA2937305C (en) 2014-02-11 2020-12-15 Brainstorm Cell Therapeutics Ltd. Pharmaceutical composition comprising bone-marrow derived mesenchymal stem cells

Also Published As

Publication number Publication date
EP3105587B1 (en) 2023-09-06
JP2017511876A (ja) 2017-04-27
WO2015121859A1 (en) 2015-08-20
IL246943A0 (en) 2016-09-29
CA2937305A1 (en) 2015-08-20
HK1232296A1 (zh) 2018-01-05
EP3105587A1 (en) 2016-12-21
JP6628253B2 (ja) 2020-01-08
US10564149B2 (en) 2020-02-18
CA2937305C (en) 2020-12-15
WO2015121859A8 (en) 2015-10-08
IL246943B (en) 2020-05-31
US20160334392A1 (en) 2016-11-17

Similar Documents

Publication Publication Date Title
BR112016018489A2 (pt) Método de qualificação de células, população isolada de células-tronco mesenquimais, método de tratamento de uma doença imune ou inflamatória, e uso de células-tronco mesenquimais
BR112021015887A8 (pt) Método para criopreservação de célula-tronco, população de células-tronco, composição de criopreservação, uso de nac, e kit de criopreservação
ES2813407T3 (es) Métodos para generar células madre mesenquimales que secretan factores neurotróficos
BR112016026626A2 (pt) Uso de moléculas pequenas para melhorar a expressão de mafa em células pancreáticas endócrinas
TR201904270T4 (tr) Tanımlı koşullar altında insan pluripotent kök hücrelerinin hematoendotelyal farklılaşması için yöntemler ve materyaller.
BR112018007070A2 (pt) método, composição e kit para a preparação de uma planta a partir de um protoplasto, planta regenerada e composição para clivagem de dna
BR112017014218A2 (pt) método para a oxidação eletroquímica, célula eletroquímica, método para a oxidação fotoeletroquímica e célula fotoeletroquímica
BR112018068473A2 (pt) meio de formação de colônias e uso das mesmas
CL2013002029A1 (es) Celula progenitora y no diferenciada neural humana expandible aislada; composicion que la comprende; metodo de cultivo in vitro; dicho cultivo in vitro; y su uso para tratar una condicion causada por perdida de mielina o de oligodendrocitos.
BR112018001232A2 (pt) pd-l1 que expressa células-tronco hematopoéticas e usos
BR112013004616A2 (pt) diferenciação das células tronco embrionárias humanas
SG10201903910RA (en) Differentiation-induced cell population from which undifferentiated cells have been removed, use of same, and method for producing same
MX2016005658A (es) Suspensión y agrupamiento de células madre humanas pluripotentes para la diferenciación a células endocrinas pancreáticas.
BR112017012974A2 (pt) cultura em suspensão de células-tronco pluripotentes
WO2013124815A3 (en) Mesenchymal stem cells for in vitro modeling and cell-based therapy of human diseases and banks thereof
BR112019009746A2 (pt) ensaio de células-tronco pluripotentes
BR112016030758B8 (pt) Uso de células estromais multipotentes derivadas de tecido adiposo mesenquimal
BR112017023744A2 (pt) método para obtenção de uma biomassa de uma microalga das espécies tetraselmis chuii enriquecidas em superóxido dismutase (sod)
EP3805370A4 (en) MESENCHYMATE STEM CELL DERIVED FROM HLA GENE DELETED HUMAN INDUCED PLURIPOTENT STEM CELL AND METHOD FOR PREPARING IT
BR112015030685A2 (pt) método para diferenciar células-tronco, células, biobanco de células, uso das células e composição terapêutica
BR112017019189A2 (pt) agente terapêutico celular para tratamento de câncer e terapia de combinação com o mesmo
BR112018069090A2 (pt) tratamento de câncer com base na distribuição de oligos por meio de junções comunicantes a partir de células estaminais mesenquimatosas humanas (hmsc)
BR112015017977A8 (pt) método de cultura líquida, método para obter e/ou cultivar uma cripta, cripta, usos da cripta
EP3202911A4 (en) Method for determining undifferentiated state of pluripotent stem cells by culture medium analysis
BR112018008931A8 (pt) ?compostos para tratamento de distúrbios hipoproliferativos?

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]